Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs.
M Mizobuchi, T Hineno, Y Kakimoto, K Hiratani
Index: Brain Res. 612(1-2) , 319-21, (1993)
Full Text: HTML
Abstract
Neuroendocrine abnormality of the hypothalamic-pituitary-adrenal axis was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs as a model of Parkinson's disease. Blood samples were collected every 4 h for 3-4 days before MPTP treatment, around 2 and 4 weeks after the treatment of MPTP (2.5 mg/kg). Adrenocorticotrophin (ACTH) and cortisol concentrations in plasma were determined by radioimmunoassay. The concentrations of plasma ACTH and cortisol increased by 40% and 60% after MPTP treatment, respectively. Circadian rhythms of neither plasma ACTH nor cortisol concentrations were observed in both MPTP-treated and control dogs. This high hypothalamic-pituitary-adrenal function in MPTP-treated dogs suggests that MPTP may influence the activity of the hypothalamic neurons of the dog.
Related Compounds
Related Articles:
The histochemical demonstration of MPTP oxidation in the postmortem human striatum.
1993-05-14
[Neurosci. Lett. 154(1-2) , 61-4, (1993)]
1993-04-23
[Brain Res. 609(1-2) , 98-102, (1993)]
Imidazolium salt (DBZIM) reduces gliosis in mice treated with neurotoxicant 2'-CH(3) -MPTP.
2011-06-01
[CNS Neurosci. Ther. 17(3) , 148-57, (2011)]
2002-11-01
[J. Pharmacol. Exp. Ther. 303(2) , 527-33, (2002)]
1993-11-26
[Neurosci. Lett. 163(1) , 31-5, (1993)]